✦ New CED Clinical Relevance #70 Notable Clinical Interest Emerging findings or policy developments worth monitoring closely. ⚒ Policy Watch | Federal Register PolicySafetyResearch Why This Matters I don't see an article...
Policy Watch: 16 Regulatory Updates — March 13, 2026
Policy WatchMarch 13, 2026. 16 regulatory items above the clinical relevance threshold of 40. Sources include Federal Register, regulations.gov, and regulatory RSS feeds. Listed in descending order of relevance score. Score 70Regulations.govSchedules...
Policy Watch: 25 Regulatory Updates — March 12, 2026
Policy WatchMarch 12, 2026. 25 regulatory items above the clinical relevance threshold of 40. Sources include Federal Register, regulations.gov, and regulatory RSS feeds. Listed in descending order of relevance score. Score 70Regulations.govSchedules...
Policy Watch: 20 Regulatory Updates — March 12, 2026
Policy WatchMarch 12, 2026. 20 regulatory items above the clinical relevance threshold of 40. Sources include Federal Register, regulations.gov, and regulatory RSS feeds. Listed in descending order of relevance score. Score 70Regulations.govSchedules...
Policy Watch: 16 Regulatory Updates — March 11, 2026
Policy WatchMarch 11, 2026. 16 regulatory items above the clinical relevance threshold of 40. Sources include Federal Register, regulations.gov, and regulatory RSS feeds. Listed in descending order of relevance score. Score 70Regulations.govSchedules...
AM Policy Update: March 11, 2026
AM Policy UpdateMarch 11, 2026. 20 regulatory items from Federal Register, regulations.gov, and regulatory RSS feeds. Score 85Regulations.govSchedules of Controlled Substances: Placement of Butonitazene, Flunitazene, and Metodesnitazene in Schedule IThe DEA placed...
Policy Watch: 20 Regulatory Updates — March 11, 2026
Policy WatchMarch 11, 2026. 20 regulatory items above the clinical relevance threshold of 40. Sources include Federal Register, regulations.gov, and regulatory RSS feeds. Listed in descending order of relevance score. Score 70Regulations.govSchedules...
Schedules of Controlled Substances: Placement of 2-Methyl AP-237 in Schedule I
✦ New CED Clinical Relevance #70 Notable Clinical Interest Emerging findings or policy developments worth monitoring closely. ⚒ Policy Watch | Regulations.gov PolicySafetyResearch Why This Matters I don’t see a summary provided...
Schedules of Controlled Substances: Placement of Butonitazene, Flunitazene, and Metodesnitazene Substances in Schedule I
✦ New CED Clinical Relevance #70 Notable Clinical Interest Emerging findings or policy developments worth monitoring closely. ⚒ Policy Watch | Regulations.gov PolicySafetyResearch Why This Matters This regulatory action scheduling three new...
Schedules of Controlled Substances: Placement of Etodesnitazene, N-Pyrrolidino etonitazene, and Protonitazene in Schedule I
✦ New CED Clinical Relevance #70 Notable Clinical Interest Emerging findings or policy developments worth monitoring closely. ⚒ Policy Watch | Regulations.gov PolicySafetyResearch Clinical Summary The DEA has placed three synthetic opioid...